Molecular epidemiology and its current clinical use in cancer management
作者： Mikael Hartman , En Yun Loy , Chee Seng Ku , Kee Seng Chia
DOI: 10.1016/S1470-2045(10)70005-X
关键词:
摘要: Summary The revelation of the entire human DNA sequence in 2001, and launching international haplotype map (HapMap) project, made identification common markers disease possible, dramatically transforming molecular epidemiology. In recent years, development of, discoveries within, genome research have been rapid, highlighted by current explosion genome-wide association studies (GWAS). GWAS aim at finding germline changes that increase cancer risk. An equally important rapid had seen genomics, with great strides being our understanding somatic mutations allow accompany development. this review we discuss whether it is currently possible to use these new aid reduction mortality reducing risk disease, improving prognosis, keeping complications due treatment a minimum. Findings from mostly used predict risk, but there potential them for prognostication even prediction. Expression arrays identified prognostic patterns breast cancer, few reliable are available More importantly, virtually no genetic signatures morbidity treatment. Thus, need bring different biological techniques together integrate existing clinical oncological care simultaneous outcome assessment.
elsevier.com
sci-hub.se 参考文章(89)
Therese Sørlie, Molecular classification of breast tumors: toward improved diagnostics and treatments. Methods of Molecular Biology. ,vol. 360, pp. 91- 114 ,(2007) , 10.1385/1-59745-165-7:91
Francis S Collins, Anna D Barker, Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Scientific American. ,vol. 296, pp. 50- ,(2007)
重衡 佐治, 雅代 川上, What's going on 乳癌 A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, et al. Cancer Cell. 2004;5:607-16. PMID:15193263--術後補助療法におけるタモキシフェンへの反応性は2つの遺伝子レベルの測定によって予測しうることを示した論文 Mebio oncology. ,vol. 2, pp. 94- 96 ,(2005)
L. D. Miller, J. Smeds, J. George, V. B. Vega, L. Vergara, A. Ploner, Y. Pawitan, P. Hall, S. Klaar, E. T. Liu, J. Bergh, An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival Proceedings of the National Academy of Sciences of the United States of America. ,vol. 102, pp. 13550- 13555 ,(2005) , 10.1073/PNAS.0506230102
Pia Wegman, Sauli Elingarami, John Carstensen, Olle Stål, Bo Nordenskjöld, Sten Wingren, Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer Breast Cancer Research. ,vol. 9, pp. 1- 9 ,(2007) , 10.1186/BCR1640
J. Couzin, New Haplotype Map May Overhaul Gene Hunting Science. ,vol. 310, pp. 601- 601 ,(2005) , 10.1126/SCIENCE.310.5748.601A
M. W. Audeh, R. T. Penson, M. Friedlander, B. Powell, K. M. Bell-McGuinn, C. Scott, J. N. Weitzel, J. Carmichael, A. Tutt, Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer Journal of Clinical Oncology. ,vol. 27, pp. 5500- 5500 ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.5500
Early Breast Cancer Trialists' Collaborative Group, None, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials The Lancet. ,vol. 365, pp. 1687- 1717 ,(2005) , 10.1016/S0140-6736(05)66544-0
Francis S. Collins, Anna D. Barker, Mapping the Cancer Genome Scientific American. ,vol. 296, pp. 50- 57 ,(2007) , 10.1038/SCIENTIFICAMERICAN0307-50
Angela Cox, Alison M Dunning, Montserrat Garcia-Closas, Sabapathy Balasubramanian, Malcolm WR Reed, Karen A Pooley, Serena Scollen, Caroline Baynes, Bruce AJ Ponder, Stephen Chanock, Jolanta Lissowska, Louise Brinton, Beata Peplonska, Melissa C Southey, John L Hopper, Margaret RE McCredie, Graham G Giles, Olivia Fletcher, Nichola Johnson, Isabel dos Santos Silva, Lorna Gibson, Stig E Bojesen, Børge G Nordestgaard, Christen K Axelsson, Diana Torres, Ute Hamann, Christina Justenhoven, Hiltrud Brauch, Jenny Chang-Claude, Silke Kropp, Angela Risch, Shan Wang-Gohrke, Peter Schürmann, Natalia Bogdanova, Thilo Dörk, Rainer Fagerholm, Kirsimari Aaltonen, Carl Blomqvist, Heli Nevanlinna, Sheila Seal, Anthony Renwick, Michael R Stratton, Nazneen Rahman, Suleeporn Sangrajrang, David Hughes, Fabrice Odefrey, Paul Brennan, Amanda B Spurdle, Georgia Chenevix-Trench, Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer, Jonathan Beesley, Arto Mannermaa, Jaana Hartikainen, Vesa Kataja, Veli-Matti Kosma, Fergus J Couch, Janet E Olson, Ellen L Goode, Annegien Broeks, Marjanka K Schmidt, Frans BL Hogervorst, Laura J Van't Veer, Daehee Kang, Keun-Young Yoo, Dong-Young Noh, Sei-Hyun Ahn, Sara Wedrén, Per Hall, Yen-Ling Low, Jianjun Liu, Roger L Milne, Gloria Ribas, Anna Gonzalez-Neira, Javier Benitez, Alice J Sigurdson, Denise L Stredrick, Bruce H Alexander, Jeffery P Struewing, Paul DP Pharoah, Douglas F Easton, Breast Cancer Association Consortium, None, A common coding variant in CASP8 is associated with breast cancer risk Nature Genetics. ,vol. 39, pp. 352- 358 ,(2007) , 10.1038/NG1981